ArticleFrontiers in oncology2026
The impact of inflammation on the incidence of different pathological types of lung cancer: the Kailuan study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic inflammation drives lung cancer pathogenesis; however, evidence on its association with incident risk across pathological subtypes remains limited. Objective: To evaluate associations of 15 inflammatory indicators with long-term and 10-year risk of overall and subtype specific lung cancer. Methods and results: This study included 99, 925 participants from the Kailuan cohort (mean follow-up, 14.85 years). During follow-up, 1, 804 incident lung cancer cases were identified. After multivariable adjustment and false discovery rate correction, several inflammatory markers, particularly the novel composite indices SIRI and AISI, were significantly associated with increased overall lung cancer risk. Per 1 Z-score increase, white blood cell count (HR = 1.112, 95% CI: 1.064-1.163), monocytes (HR = 1.060, 95% CI: 1.033-1.087), lymphocytes (HR = 1.050, 95% CI: 1.014-1.087), neutrophils (HR = 1.083, 95% CI: 1.037-1.130), CLR (HR = 1.031, 95% CI: 1.006-1.058), SIRI (HR = 1.536, 95% CI: 1.183-1.995), and AISI (HR = 1.070, 95% CI: 1.023-1.119) showed significant associations. For 10-year risk, similar associations were observed, with SIRI and AISI increasing risk by 75.7% (HR = 1.757, 95% CI: 1.350-2.278) and 9.0% (HR = 1.090, 95% CI: 1.029-1.154), respectively. Subtype analyses revealed significant positive associations for squamous cell carcinoma (e.g., SIRI: HR = 1.782, 95% CI: 1.352-2.350) and other pathological types (e.g., SIRI: HR = 1.638, 95% CI: 1.263-2.125) but not for adenocarcinoma or small cell lung cancer. Stratified analyses showed effect modification by age for SIRI in overall lung cancer (stronger in participants aged ≥60 years), and by sex, age, and smoking status for multiple markers in subtype-specific analyses. SIRI showed the strongest effects across all analyses. Conclusion: Chronic inflammation is differentially associated with lung cancer risk by subtype; SIRI and AISI are independent risk factors, with SIRI showing the strongest effects, particularly for squamous cell carcinoma, in individuals aged ≥ 60 years, and these associations are modified by sex and smoking status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.